DrugPatentWatch Database Preview

Pharmacyclics Inc Company Profile

« Back to Dashboard

What is the competitive landscape for PHARMACYCLICS INC, and when can generic versions of PHARMACYCLICS INC drugs launch?

PHARMACYCLICS INC has two approved drugs.

There are twenty-seven US patents protecting PHARMACYCLICS INC drugs.

There are two hundred and six patent family members on PHARMACYCLICS INC drugs in thirty-eight countries and twenty-three supplementary protection certificates in eleven countries.

Summary for Pharmacyclics Inc

International Patents:	206
US Patents:	27
Tradenames:	1
Ingredients:	1
NDAs:	2

Drugs and US Patents for Pharmacyclics Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacyclics Inc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-003	Feb 16, 2018		RX	Yes	No	9,801,881
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-001	Nov 13, 2013		RX	Yes	Yes	8,703,780
Pharmacyclics Inc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-004	Feb 16, 2018		RX	Yes	Yes	8,754,090
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No	9,801,881
Pharmacyclics Inc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-003	Feb 16, 2018		RX	Yes	No	9,795,604
Pharmacyclics Inc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-001	Feb 16, 2018		RX	Yes	No	8,735,403		Y	Y
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No	9,801,883

Non-Orange Book US Patents for Pharmacyclics Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,133,198	Inhibitors of bruton'S tyrosine kinase
8,501,751	Inhibitors of Bruton's tyrosine kinase
8,735,404	Inhibitors of Bruton's tyrosine kinase
8,232,280	Inhibitors of bruton'S tyrosine kinase
8,236,812	Inhibitors of bruton's tyrosine kinase
9,193,735	Inhibitors of Bruton's tyrosine kinase
8,975,266	Inhibitors of Bruton's tyrosine kinase

International Patents for Pharmacyclics Inc Drugs

Country	Document Number	Estimated Expiration
Portugal	2530083
Singapore	10201503235V
Spain	2617150
Eurasian Patent Organization	201270793
Singapore	10201508035T
Taiwan	201402122
European Patent Office	2139487

Supplementary Protection Certificates for Pharmacyclics Inc Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2015017,C2201840	Lithuania		PRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 20141021
2016000093	Germany		PRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20160526
C0029	France		PRODUCT NAME: IBRUTINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/945 20141023
/2015	Austria		PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ; REGISTRATION NO/DATE: EU/1/14/945 20141021
692	Luxembourg		PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20141023
0868	Netherlands		PRODUCT NAME: IBRUTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/14/945 - C(2015)4704 20150707
2015000027	Germany		PRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20141021

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Pharm Assoc
• Pharm Res Assoc
• Pharm Spec
• Pharm Ventures
• Pharma Res Software
• Pharma Serve Ny
• Pharmacare